AriBio, Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AriBio, Co., Ltd. - overview
Established
2010
Location
Seongnam, Gyeonggi Province, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam, South Korea, and founded in 2010, AriBio develops an artificial intelligence-powered, reserve-engineered, and integrated drug development (AIRDD) platform for neurodegenerative diseases. In January 2022, AriBio raised KRW 34. 5 billion in pre-IPO funding from Mason Capital and Cactus Private Equity. As of January 2024, the company is led by CEO Jai Jun Choung.
The business offers an AIRDD multi-mechanism medication for neurodegenerative disorders like Alzheimer's, which are caused by a combination of hereditary, environmental, and psychological factors. The platform uses AI to engage drugs across various targets and mechanisms in a large chemical database. The company's solutions for Alzheimer's disease, prodromal illness, and rent syndrome are in the enabling stage, while moderate cognitive impairment and dementia with lewy bodies are in phase 2.
Current Investors
WOORI Venture Partners, Korea Credit Guarantee Fund, Cactus Private Equity
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare IT, Pharmaceutical Research & Development
Website
www.aribio.com
Verticals
Artificial Intelligence, HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.